AzTrials
AzTrials

Uncontrolled HypertensionEuroNetrodNCT06722651

EuroNetrod HTN OFF-Med Study of Renal Denervation With NetrodTM Six-electrode Radiofrequency RDN System

A study testing Netrod™ six-electrode radiofrequency renal denervation system in people with Uncontrolled Hypertension, run by Shanghai Golden Leaf MedTec Co. Ltd at 1 site in Switzerland.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This randomized controlled investigation aims to evaluate the efficacy and safety of the Netrod™ RDN system in patients with uncontrolled primary hypertension in the absence of antihypertensive medication, comparing the outcomes between renal denervation, sham procedure, and open-label control groups. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Uncontrolled Hypertension
What is being tested?
Netrod™ six-electrode radiofrequency renal denervation system
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
0 participants
Where
1 siteSwitzerland
Study dates
30 Aug 2025to Aug 2031
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject with age ≥18 years or minimum age as required by local regulations and ≤80 years old at time of consent
  • Subject with hypertension who has an office BP of ≥150/90 mmHg and <180/110 mmHg (meet both SBP and DBP criteria) at screening V3 and mean daytime ASBP ≥140 mmHg and <170 mmHg by 24-hour ABPM at Screening V3
  • Subject or his/her legal representative must sign an IEC/REB-approved ICF for the study
  • Subject is willing to discontinue current antihypertensive medications at Screening V1 through the 3-month follow-up visit

Who cannot join

  • 1. Subject who is pregnant, nursing or planning to become pregnant during the course of the study
  • Subject with unilateral or bilateral renal artery that are not suitable for ablation procedure (renal artery stenosis more than 50%, renal aneurysm, renal artery abnormality, renal artery diameter <3 mm or treatable segment length <20 mm)
  • Subject with single-kidney or history of kidney transplant
  • Subject with history of renal artery intervention (PTA or stenting) or RDN
  • Subject with any conditions that may affect the accuracy of blood pressure measurement: such as the diameter of the upper arm is too large for the cuff, or arrhythmia, etc.
  • Subject with known secondary hypertension
Show all 36Show fewer
  • Subject with eGFR <40 mL/min/l.73m²
  • Subject with history of hospitalization for hypertensive emergency within past year
  • Subject with type I diabetes mellitus
  • Subject with primary pulmonary hypertension
  • Subject with history of bleeding diathesis and haematological disorders or coagulopathy
  • Subject with recent history of any embolism within 6 months
  • Subject with history of coronary artery intervention, unstable angina or myocardial infarction
  • Subject with stable angina and therefore treated anti-anginal medication (betablockers, calcium antagonists, long-acting nitrates)
  • Subject with history of abdominal aortic aneurysm
  • Subject with atrial fibrillation or history of atrial fibrillation in the last 3 years or on rhythm control medication for arrhythmia
  • Subject with a history of ventricular fibrillation or ventricular tachycardia
  • Subject known with serum HIV-positive
  • Subject who is allergic to contrast agents and not responding to preventive medication
  • Subject with acute or severe systemic infections
  • Subject with mental illness or any psychological problems that may interfere with participating in the study
  • Subject with history of stroke or transient ischemic attack (TIA)
  • Subject with malignant tumors or end-stage disease
  • Subject with severe PAD along the access path to renal arteries, including abdominal aneurysm
  • Subject with severe heart valve stenosis or regurgitation
  • Subject with heart failure requiring medications (i.e. ACE/ARB, SGTL2i, diuretics).
  • Subject with uncontrolled hyperthyroidism or hypothyroidism
  • Subject with severe electrolyte abnormalities, defined as values above and below the limits of normal (ULN) on repeated measurements despite normalization efforts, or with liver function abnormalities, defined as 2 > ULN
  • Subject who requires mechanical ventilation other than CPAP for sleep apnea
  • Subject with a implanted pacemaker or ICD/CRT device
  • Subject with a history of major surgery or trauma within 30 days prior to enrolment
  • Subject who has planned surgery or cardiovascular intervention within the next 12 months
  • Subject who is participating in other drug or medical device clinical investigations
  • Subject who has known drug or alcohol dependence, difficulty to understand the clinical investigation protocol, inability/unwillingness to follow the clinical investigation protocol
  • Subject who is unsuitable to participate in this study in the opinion of investigators
  • Subjects who are incapacitated or unable to provide informed consent due to cognitive impairment, mental illness, or other conditions that affect their decision-making capacity.

Trial locations and contacts

1 site in 1 country.

Switzerland1 site

  • University Hospital Basel

    Basel, Canton of Basel-City, Switzerland

Other trials in Switzerland

About this study

Official title: Randomized Controlled Clinical Study to Evaluate the Novel Netrod™ Renal Denervation System and the Impact of Sham vs Open-Label Control in European Patients With Uncontrolled Primary Hypertension in the Absence of Hypertensive Medication

This randomized controlled investigation aims to evaluate the efficacy and safety of the Netrod™ RDN system in patients with uncontrolled primary hypertension in the absence of antihypertensive medication, comparing the outcomes between renal denervation, sham procedure, and open-label control groups.

Read the detailed description

This is a prospective, multi-center, blinded, three-arm randomized controlled study to demonstrate the effectiveness and safety of the Netrod™ RDN system for treating treating patients with uncontrolled primary hypertension in the absence of antihypertensive medications. This clinical investigation will enroll 260 patients in Europe. Patients with uncontrolled primary hypertension (office BP ≥150/90 mmHg and <180/110 mmHg) who are willing to discontinue antihypertensive medications will be screened after providing informed consent.

All eligible patients will undergo a medication washout period of at least three weeks, and those who continue to meet the eligibility requirements will be randomized in a 2:1:1 ratio to one of three groups: renal denervation (RDN), a sham procedure (renal artery angiogram only), or an open-label group (not undergoing the renal angiogram).

All subjects randomized to either the treatment or sham procedure groups will be evaluated at hospital discharge. All subjects will be evaluated at 1 and 3 months post-procedure. Additionally, patients who undergo the RDN procedure will also be evaluated at 12, 24, and 36 months post-procedure. All subjects will remain off antihypertensive medications until the primary endpoint is assessed at the 3-month follow-up visit, after which antihypertensive medications may be reintroduced.

Patients in the RDN and sham-control groups, as well as all clinical follow-up assessors, will be blinded to the treatment allocation. The primary efficacy endpoint is the change in daytime ambulatory systolic blood pressure (ASBP) from baseline at three months post-procedure. The primary safety endpoint is the periprocedural major adverse event (MAE) rate at 30 days post-procedure.

Subjects enrolled in the sham and open-label control groups may cross over to RDN at three months. Those who cross over will restart the follow-up schedule post-RDN procedure.

Being tested
Netrod™ six-electrode radiofrequency renal denervation system, Sham Procedure
Keywords
Renal denervation (RDN), Radiofrequency renal denervation, Sympathetic nervous system, Interventional therapy, Interventional cardiology, Device-based therapy, Renal artery denervation, Blood pressure, Resistant Hypertension, Refractory Hypertension
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Netrod™ six-electrode radiofrequency renal denervation systemDevice

    Netrod™ renal denervation (RDN) system, which is indicated for the treatment of uncontrolled hypertension. It consists of the following two components:

    • Netrod™ Six-Electrode Basket Radiofrequency Renal Denervation Catheter and
    • Netrod™ Renal Denervation Radiofrequency Generator The catheter's electrodes deploy into a self-adaptive basket structure, optimizing contact with the vessel wall for effective ablation.

  • Sham ProcedureDevice

    Patients will be remained on the catheterization table for at least 20 min prior to sheath removal.

Study groups in NCT06722651
Study groupRoleWhat they receive
Renal DenervationExperimentalRenal angiogram and Renal Denervation procedure
Receives: Device: Netrod™ six-electrode radiofrequency renal denervation system
Sham Control groupSham comparatorRenal angiogram followed by Sham procedure
Receives: Device: Sham Procedure
Open-label Control groupNo interventionThe patient will not undergo either the renal angiogram or the RDN procedure.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean daytime ambulatory systolic blood pressure

    Between-group difference in baseline adjusted change in mean daytime ambulatory systolic blood pressure (ASBP) at 3 months compared to baseline measured by 24 hours ambulatory blood pressure monitoring (ABPM) (RDN vs sham vs open-label).

    Measured: From baseline at Screening Visit 2 to Month 3 post-procedure

  2. Periprocedural major adverse event (MAE) rate

    Periprocedural major adverse event (MAE) rate, defined as a composite of the following events at 30 days post procedure:

    • All-cause mortality
    • End-stage renal disease (ESRD) defined as stage 5 CKD (eGFR < 15 mL/min/l.73m²) or hemodialysis
    • Significant embolic event resulting in end-organ damage
    • Renal artery perforation or dissection requiring intervention
    • Major vascular complications requiring medical or surgical intervention
    • Hospitalization for hypertensive crisis (unless clearly demonstrated to be associated with non-adherence with antihypertensive medications in the subjects on escape medication)
    • New renal artery stenosis > 70% (must be confirmed by angiography)

    Measured: At 30 days post-procedure

Secondary outcomes (9)

  1. Office blood pressure (BP) and home BP

    Changes from baseline in office blood pressure (BP) and home BP at 1- and 3-month post procedure for all enrolled subjects, and 12-, 24- and 36-month post procedure for the subjects who underwent RDN

    Measured: From baseline at Screening Visit 2 to Month 1, 3, 12, 24 and 36 post-procedure

  2. Mean ambulatory BP including 24-hour ASBP and ADBP, daytime and nighttime SBP and DBP

    Changes from baseline in mean ambulatory BP including 24-hour ASBP and ADBP, daytime and nighttime SBP and DBP measured by 24-hour ABPM at 1-, 3-month for all enrolled subjects, and 12-, 24- and 36-month for the subjects who underwent RDN.

    Measured: From baseline at Screening Visit 2 to Month 1, 3, 12, 24 and 36 post-procedure

  3. Percentage of patients with office systolic BP (SBP) within the target range (SBP <140 mmHg)

    Percentage of patients with office systolic BP (SBP) within the target range (SBP <140 mmHg) at 3-month post procedure for all enrolled subjects, and 12-, 24- and 36-month post procedure for the subjects who underwent RDN

    Measured: At Month 3, 12, 24 and 36 post-procedure

  4. Percentage of patients with office systolic blood pressure (SBP) within the target range (SBP <130 mmHg)

    Percentage of patients with office systolic blood pressure (SBP) within the target range (SBP <130 mmHg) at 3-month post procedure for all enrolled subjects, and 12-, 24- and 36-month post procedure for the subjects who underwent RDN

    Measured: At Month 3, 12, 24 and 36 post-procedure

  5. Percentage of patients with mean ambulatory systolic blood pressure (ASBP) within the target range (SBP <130 mmHg)

    Percentage of patients with mean ambulatory systolic blood pressure (ASBP) within the target range (SBP <130 mmHg) at 3-month post procedure for all enrolled subjects, and 12-, 24- and 36-month post procedure for the subjects who underwent RDN

    Measured: At Month 3, 12, 24 and 36 post-procedure

  6. The proportion of ambulatory SBP decreased by 5 and 10 mmHg

    The proportion of ambulatory SBP decreased by 5 and 10 mmHg at 3-month post procedure

    Measured: At Month 3 post-procedure

  7. Safety event rates

    The following safety event rates to 3-month post procedure for all enrolled subjects, and the following event rates at 12-, 24- and 36-month post procedure for the subjects who underwent RDN procedure:

    • All-cause mortality
    • End-stage renal disease (ESRD) defined as stage 5 CKD (eGFR < 15 mL/min/l.73m²)
    • ≥50% decline in eGFR or >50% increase in serum creatinine from baseline
    • New myocardial infarction or acute coronary syndrome (ACS)
    • New stroke or CVA
    • Renal artery reintervention
    • New renal artery stenosis > 70% confirmed by angiography
    • Hospitalization for hypertensive crisis not related to confirmed non-adherence of antihypertensive medications
    • Hospitalization for major cardiovascular- or hemodynamic-related events (such as heart failure or atrial fibrillation)

    Measured: At Month 3 post-procedure

  8. Device deficiency rates

    Device deficiency rates

    Measured: At Visit 4, day 0 (procedure)

  9. Quality of life changes

    Quality of life changes at 12 months and annually through 3 years post index procedure

    Measured: From baseline at Screening Visit 2 to Month 3, 12, 24 and 36 post-procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Dec 2024
  2. Study start30 Aug 2025 (estimated)
  3. Primary completionNov 2028 (estimated)
  4. Study completionAug 2031 (estimated)

Why it stopped: This decision aims to concentrate resources on accelerating the development of the next generation of the NetrodTM RDN System.This reflects a broader strategy to advancing more effective solutions for physicians and patients.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be randomly assigned to either the RDN procedure, sham procedure, or open-label control (where patients do not receive any procedure and are off medication until primary endpoint measurement). After primary endpoint measurements at Month 3, patients in the sham and open-label control groups will have the option to receive the RDN procedure, referred to as "crossover patients."
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06722651
Sponsor's protocol ID
SGL-01
Acronym
EuroNetrod
Status last verified
Jul 2025
First submitted
15 Nov 2024
Last updated
31 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Li Y, Gao F, Ren C, Ma G, Bu P, Fu G, Chen H, Han Z, Li Y, Li J, Ma X, Hao L, Chen Y, Chen M, Chen X, Liu X, Jiang J, Yu J, Li N, Ma X, Yang B, Cong H, Wang X, Fan Q, Lv S, Wu D, Dai Q, Qiu F, Cai H, Zhou YJ. The Netrod six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial. Eur Heart J. 2024 Nov 21;45(44):4761-4764. doi: 10.1093/eurheartj/ehae703. No abstract available.

    PubMed 39431289

Questions about this trial

What is this clinical trial studying?

A study testing Netrod™ six-electrode radiofrequency renal denervation system in people with Uncontrolled Hypertension, run by Shanghai Golden Leaf MedTec Co. Ltd at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 31 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean daytime ambulatory systolic blood pressure (time frame: From baseline at Screening Visit 2 to Month 3 post-procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06722651, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in